AU779086B2 - Neisserial vaccine compositions and methods - Google Patents
Neisserial vaccine compositions and methods Download PDFInfo
- Publication number
- AU779086B2 AU779086B2 AU26811/00A AU2681100A AU779086B2 AU 779086 B2 AU779086 B2 AU 779086B2 AU 26811/00 A AU26811/00 A AU 26811/00A AU 2681100 A AU2681100 A AU 2681100A AU 779086 B2 AU779086 B2 AU 779086B2
- Authority
- AU
- Australia
- Prior art keywords
- neisseria
- commensal
- composition according
- composition
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 35
- 229960005486 vaccine Drugs 0.000 title claims abstract description 35
- 241001212279 Neisseriales Species 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 241000588653 Neisseria Species 0.000 claims abstract description 94
- 208000015181 infectious disease Diseases 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 241000588649 Neisseria lactamica Species 0.000 claims description 43
- 241000588650 Neisseria meningitidis Species 0.000 claims description 29
- 239000012528 membrane Substances 0.000 claims description 23
- 230000002163 immunogen Effects 0.000 claims description 18
- 238000002255 vaccination Methods 0.000 claims description 16
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 12
- 239000003599 detergent Substances 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 11
- 241000588654 Neisseria cinerea Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 6
- 101000812705 Gallus gallus Endoplasmin Proteins 0.000 claims description 5
- 108010013381 Porins Proteins 0.000 claims description 5
- 208000034762 Meningococcal Infections Diseases 0.000 claims description 4
- 241000588645 Neisseria sicca Species 0.000 claims description 4
- 101710116435 Outer membrane protein Proteins 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 108010052285 Membrane Proteins Proteins 0.000 claims description 3
- 102000018697 Membrane Proteins Human genes 0.000 claims description 3
- 241000588673 Neisseria elongata Species 0.000 claims description 3
- 241000588651 Neisseria flavescens Species 0.000 claims description 3
- 241001136170 Neisseria subflava Species 0.000 claims description 3
- 241000588660 Neisseria polysaccharea Species 0.000 claims description 2
- 102000007739 porin activity proteins Human genes 0.000 claims 2
- 230000002906 microbiologic effect Effects 0.000 claims 1
- 230000005180 public health Effects 0.000 claims 1
- 208000037941 meningococcal disease Diseases 0.000 abstract description 15
- 230000000813 microbial effect Effects 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 description 26
- 239000000047 product Substances 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 230000000890 antigenic effect Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- PZZHMLOHNYWKIK-UHFFFAOYSA-N eddha Chemical compound C=1C=CC=C(O)C=1C(C(=O)O)NCCNC(C(O)=O)C1=CC=CC=C1O PZZHMLOHNYWKIK-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000058953 Neisseria lactamica Y92-1009 Species 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010028253 Measles virus nucleoprotein Proteins 0.000 description 3
- 102000017033 Porins Human genes 0.000 description 3
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 101150006844 groES gene Proteins 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 3
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229960004906 thiomersal Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 101100439426 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) groEL4 gene Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 229910017518 Cu Zn Inorganic materials 0.000 description 1
- 229910017752 Cu-Zn Inorganic materials 0.000 description 1
- 229910017943 Cu—Zn Inorganic materials 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027249 Meningitis meningococcal Diseases 0.000 description 1
- 201000010924 Meningococcal meningitis Diseases 0.000 description 1
- 206010027280 Meningococcal sepsis Diseases 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000008267 Peanut Hypersensitivity Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108010042038 Protozoan Proteins Proteins 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 101150023858 frpC gene Proteins 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 101150077981 groEL gene Proteins 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 201000010853 peanut allergy Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9904028.9A GB9904028D0 (en) | 1999-02-22 | 1999-02-22 | Neisserial vaccine |
| GB9904028 | 1999-02-22 | ||
| GBGB9922561.7A GB9922561D0 (en) | 1999-09-23 | 1999-09-23 | Neisserial vaccine compositions and methods |
| GB9922561 | 1999-09-23 | ||
| PCT/GB2000/000624 WO2000050074A2 (en) | 1999-02-22 | 2000-02-22 | Neisserial vaccine compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2681100A AU2681100A (en) | 2000-09-14 |
| AU779086B2 true AU779086B2 (en) | 2005-01-06 |
Family
ID=26315168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU26811/00A Ceased AU779086B2 (en) | 1999-02-22 | 2000-02-22 | Neisserial vaccine compositions and methods |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7157245B2 (enExample) |
| EP (2) | EP1852125A3 (enExample) |
| JP (1) | JP4982009B2 (enExample) |
| AT (1) | ATE386541T1 (enExample) |
| AU (1) | AU779086B2 (enExample) |
| CA (1) | CA2371928C (enExample) |
| CY (1) | CY1107950T1 (enExample) |
| DE (1) | DE60038099T2 (enExample) |
| DK (1) | DK1154791T3 (enExample) |
| ES (1) | ES2298128T3 (enExample) |
| PT (1) | PT1154791E (enExample) |
| WO (1) | WO2000050074A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1154791T3 (da) * | 1999-02-22 | 2008-06-16 | Health Prot Agency | Neisseria-vaccinesammensætninger og fremgangsmåder |
| US7081244B2 (en) * | 1999-02-22 | 2006-07-25 | Health Protection Agency | Neisserial vaccine compositions and methods |
| GB0007433D0 (en) * | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Recombinant transferrin binding proteins |
| GB0107219D0 (en) * | 2001-03-22 | 2001-05-16 | Microbiological Res Authority | Immunogenic commensal neisseria sequences |
| GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
| EP1374892A1 (en) * | 2002-06-28 | 2004-01-02 | Braun, Jan Matthias, Dr. | Medicament for the treatment of diseases due to infection by Neisseria Meningitidis |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| WO2005030122A2 (en) * | 2003-08-13 | 2005-04-07 | Chiron Corporation | Inactivated host cell delivery of polynucleotides encoding immunogens |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| US9387239B2 (en) | 2008-05-30 | 2016-07-12 | U.S. Army Medical Research And Materiel Command | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| GB0916557D0 (en) | 2009-09-21 | 2009-10-28 | Health Prot Agency | Commensal neisserial stress protein complexes |
| GB0922224D0 (en) | 2009-12-21 | 2010-02-03 | Hiltech Developments Ltd | Transformation of commensal neisseria |
| US10900043B2 (en) | 2014-09-02 | 2021-01-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating bacterial disease |
| US10286016B2 (en) | 2014-09-02 | 2019-05-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating gonorrhea |
| GB201522153D0 (en) * | 2015-12-15 | 2016-01-27 | Univ Southampton | Meningococcal infection and modified neisseria lactamica |
| US12005110B2 (en) | 2019-02-14 | 2024-06-11 | University Of Florida Research Foundation, Incorporated | Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029412A1 (en) * | 1995-03-17 | 1996-09-26 | Biochem Vaccines Inc. | Proteinase k resistant surface protein of neisseria meningitidis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288617A (en) | 1984-10-31 | 1994-02-22 | Commonwealth Scientific And Industrial Research Organization | Method of producing an antigenic preparation |
| US6737521B1 (en) * | 1990-05-11 | 2004-05-18 | The Rockefeller University | Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria |
| US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| US5470740A (en) * | 1993-11-04 | 1995-11-28 | Life Technologies, Inc. | Cloned NsiI restriction-modification system |
| US5980912A (en) | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| GB9811260D0 (en) * | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel compounds |
| GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| US20030215469A1 (en) * | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
| US6413768B1 (en) * | 1998-12-02 | 2002-07-02 | University Of Maryland | Expression plasmids |
| JP2003506007A (ja) * | 1998-12-02 | 2003-02-18 | ユニヴァーシティ オブ メリーランド，ボルチモア | 抗原送達用プラスミド維持系 |
| US7081244B2 (en) * | 1999-02-22 | 2006-07-25 | Health Protection Agency | Neisserial vaccine compositions and methods |
| DK1154791T3 (da) * | 1999-02-22 | 2008-06-16 | Health Prot Agency | Neisseria-vaccinesammensætninger og fremgangsmåder |
| GB0130123D0 (en) * | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
-
2000
- 2000-02-22 DK DK00905182T patent/DK1154791T3/da active
- 2000-02-22 PT PT00905182T patent/PT1154791E/pt unknown
- 2000-02-22 EP EP07012248A patent/EP1852125A3/en not_active Withdrawn
- 2000-02-22 WO PCT/GB2000/000624 patent/WO2000050074A2/en not_active Ceased
- 2000-02-22 CA CA2371928A patent/CA2371928C/en not_active Expired - Fee Related
- 2000-02-22 ES ES00905182T patent/ES2298128T3/es not_active Expired - Lifetime
- 2000-02-22 AU AU26811/00A patent/AU779086B2/en not_active Ceased
- 2000-02-22 EP EP00905182A patent/EP1154791B1/en not_active Expired - Lifetime
- 2000-02-22 AT AT00905182T patent/ATE386541T1/de active
- 2000-02-22 JP JP2000600684A patent/JP4982009B2/ja not_active Expired - Fee Related
- 2000-02-22 DE DE60038099T patent/DE60038099T2/de not_active Expired - Lifetime
-
2001
- 2001-08-31 US US09/942,583 patent/US7157245B2/en not_active Expired - Fee Related
-
2008
- 2008-05-19 CY CY20081100518T patent/CY1107950T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029412A1 (en) * | 1995-03-17 | 1996-09-26 | Biochem Vaccines Inc. | Proteinase k resistant surface protein of neisseria meningitidis |
Non-Patent Citations (2)
| Title |
|---|
| AOUN,L ET AL. (1998) ANN. INST. PASTEUR/MICROBIOL.139:203-12 * |
| CANN, K.J. & ROGERS, T.R. (1989) J. MED. MICROBIOL. 30:23-30 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4982009B2 (ja) | 2012-07-25 |
| EP1154791B1 (en) | 2008-02-20 |
| CY1107950T1 (el) | 2013-09-04 |
| CA2371928A1 (en) | 2000-08-31 |
| CA2371928C (en) | 2013-08-13 |
| EP1154791A2 (en) | 2001-11-21 |
| AU2681100A (en) | 2000-09-14 |
| EP1852125A2 (en) | 2007-11-07 |
| WO2000050074A2 (en) | 2000-08-31 |
| ATE386541T1 (de) | 2008-03-15 |
| EP1852125A3 (en) | 2010-09-22 |
| PT1154791E (pt) | 2008-05-30 |
| DE60038099T2 (de) | 2009-02-19 |
| DK1154791T3 (da) | 2008-06-16 |
| DE60038099D1 (de) | 2008-04-03 |
| ES2298128T3 (es) | 2008-05-16 |
| JP2002537352A (ja) | 2002-11-05 |
| US20030026809A1 (en) | 2003-02-06 |
| WO2000050074A3 (en) | 2000-12-28 |
| US7157245B2 (en) | 2007-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU779086B2 (en) | Neisserial vaccine compositions and methods | |
| US6558677B2 (en) | Vaccine against gram negative bacteria | |
| EP0453024B1 (en) | Actinobacillus pleuropneumoniae subunit vaccine | |
| US7081244B2 (en) | Neisserial vaccine compositions and methods | |
| GB2370772A (en) | Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis | |
| US11633466B2 (en) | Enteric fever vaccine based on outer membrane vesicles from two different strains of typhoidal Salmonelle species | |
| NO175735B (no) | Fremgangsmåte ved fremstilling av Pasteurella-vaksine | |
| Olivera et al. | Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection | |
| HU213924B (en) | Method for producing vaccine against enteric infection caused by enterotoxigenic e.coli bacteria in humans, containing formalin-killed e.coli strain having the ability of expressing colonization factor antigens | |
| PT90310B (pt) | Processo para a obtencao de preparacoes de adenilato-ciclase | |
| CA1331445C (en) | Vaccine against e. coli septicaemia in poultry | |
| Srivastava | Immunogenicity of Pasteurella multocida grown in iron-restricted medium | |
| CA2668883C (en) | Procedure for expressing a tbpb protein on the bacterial surface of an attenuated oral live vaccine as prototype of a meningitis b vaccine | |
| CN108619507A (zh) | 呼吸道合胞病毒-流脑联合疫苗及其制备方法 | |
| US20220054615A1 (en) | Pertussis booster vaccine | |
| EP1123711B1 (en) | Attenuated toxins as adjuvants | |
| KR101991577B1 (ko) | 다수의 에피토프로 구성된 재조합 항원 단백질 및 이의 제조방법 | |
| CN101448522A (zh) | 包含蛋白质nmb0938的药物组合物 | |
| Papezova et al. | Comparison of live and inactivated Salmonella Typhimurium vaccines containing different combinations of SPI-1 and SPI-2 antigens in poultry | |
| CA2081950A1 (en) | Vaccine for the prevention of infections caused by pasteurella haemolytica | |
| KR100829380B1 (ko) | 파스튜렐라 멀토시다 균주의 재조합 외막단백질 ｈ를이용한 가금 콜레라 백신 | |
| Robinson | Neisserial vaccine compositions and methods | |
| Byeon et al. | Generation of an attenuated Salmonella-delivery strains expressing adhesin and toxin antigens for progressive atrophic rhinitis, and evaluation of its immune responses in a murine model | |
| EP1977761A2 (en) | Pharmaceutical compositions containing protein nma0939 | |
| Handijatno | Development of a Recombinant (rOMP36) Vaccine from Pasteurella Multocida A: 1 Against Pasteurellosis in Chickens and Ducks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase | ||
| TH | Corrigenda |
Free format text: IN VOL 14, NO 48, PAGE(S) 8803-8806 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 26811/00 |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: MICROBIOLOGICAL RESEARCH AUTHORITY, PUBLIC HEALTH Free format text: THE FORMER OWNER WAS: MICROBIOLOGICAL RESEARCH AUTHORITY, IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE, PUBLIC HEALTH LABORATORY SERVICE BOARD |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTORS' NAMES TO INCLUDE: CLIONA ANNE O'DWYER |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: IMPERIAL COLLEGE INNOVATIONS LTD., THE HEALTH PROT Free format text: THE FORMER OWNER WAS: MICROBIOLOGICAL RESEARCH AUTHORITY, PUBLIC HEALTH LABORATORY SERVICE BOARD, IMPERIAL COLLEGE INNOVATIONS LTD. |